<DOC>
	<DOCNO>NCT01931787</DOCNO>
	<brief_summary>This pilot clinical trial study CPI-613 ( 6,8-bis [ benzylthio ] octanoic acid ) treat patient relapse refractory small cell lung cancer . CPI-613 may interfere growth tumor cell may effective treatment small cell lung cancer .</brief_summary>
	<brief_title>CPI-613 Treating Patients With Relapsed Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety anti-cancer activity patient relapse refractory small cell lung cancer ( SCLC ) fail 1 2 line chemotherapy . OUTLINE : Patients receive CPI-613 intravenously ( IV ) 2 hour day 1 4 week 1-3 . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histologically cytologically proven SCLC relapse refractory least one line chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 3 Expected survival &gt; 1 month No acute toxicities previous treatment high grade 1 start treatment CPI613 Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use accepted contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) study , must negative serum urine pregnancy test within 1 week prior treatment initiation Men must practice effective contraceptive method study , unless documentation infertility exist Platelet count &gt; = 100,000 cells/mm^3 &gt; = 100 bil/L Absolute neutrophil count ( ANC ) &gt; = 1500 cells/mm^3 &gt; = 1.5 bil/L Aspartate aminotransferase ( AST/serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 3 x upper normal limit ( UNL ) Bilirubin = &lt; 1.5 x UNL Serum creatinine = &lt; 1.5 mg/dL 133 Âµmol/L Albumin &gt; 2.0 g/dL &gt; 20 g/L Mentally competent , ability understand willingness sign Institutional Review Board ( IRB ) approve write informed consent form Have access via central line ( e.g. , portacath ) double lumen due CPI613 administration requirement Patients receive standard investigational treatment cancer , investigational agent noncancer indication within past 2 week prior initiation CPI613 treatment Serious medical illness would potentially increase patient ' risk toxicity Any active uncontrolled bleeding bleed diathesis Pregnant woman , woman childbearing potential use reliable mean contraception , lactate woman Men unwilling practice contraceptive method study period Life expectancy le 1 month Treatment anticancer therapy within 2 week prior treatment CPI613 Patients untreated central nervous system ( CNS ) epidural tumor Any condition abnormality may , opinion investigator , compromise safety Unwilling unable follow protocol requirement Active heart disease include myocardial infarction within previous 6 month , symptomatic coronary artery disease , arrhythmias control medication , symptomatic congestive heart failure Evidence active infection serious infection ( e.g. , septic shock multiorgan dysfunction ) within past month Patients know human immunodeficiency virus ( HIV ) infection Requirement immediate palliative treatment kind include surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>